UCB - Sales Revenues

Stock Price
249.60
Daily Change
-3.00 -1.19%
Monthly
-11.08%
Yearly
38.78%
Q1 Forecast
243.41

UCB reported EUR3.49B in Sales Revenues for its fiscal semester ending in June of 2025.





Sales Change Date
Alcon AG USD 2.7B 110M Dec/2025
Almirall EUR 547.63M 12.83M Dec/2025
Amarin USD 49.67M 23.07M Sep/2025
argenx SE USD 1.12B 132.91M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Bayer EUR 11.44B 1.78B Dec/2025
Galapagos EUR 900.82M 835.52M Dec/2025
Genmab DKK 5.86B 580M Jun/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
GRIFOLS EUR 1.98B 110M Dec/2025
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.25B 70M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Orion EUR 695.3M 272.1M Dec/2025
Recordati EUR 662M 37.65M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
UCB EUR 3.49B 129M Jun/2025
Unibail Rodamco EUR 1.57B 357.7M Jun/2025